Last reviewed: June 29, 2026

Last updated: June 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic (semaglutide) became a household name for weight loss, yet the FDA has never approved it for that indication. The medication's manufacturer, Novo Nordisk, developed a separate drug—Wegovy—specifically for weight management. Understanding this regulatory distinction reveals how precision health platforms like PlexusDx help patients access compounded semaglutide tailored to their individual needs.

The FDA Approval Gap Between Ozempic and Wegovy

Ozempic received FDA clearance in 2017 for type 2 diabetes control, with proven effects on blood glucose and cardiovascular outcomes. In 2021, Novo Nordisk secured separate FDA approval for Wegovy—a higher-dose semaglutide formulation designed specifically for chronic weight management in adults with obesity or overweight plus comorbidities. Both contain the same active pharmaceutical ingredient, but the FDA treats them as distinct therapeutic products because they target different medical conditions and use different dosing protocols.

This regulatory separation protects patient safety and ensures each medication meets specific efficacy and safety standards for its labeled indication. Ozempic's approval pathway examined diabetes outcomes over 30+ weeks, while Wegovy's studies focused on weight loss sustainability over 68 weeks in non-diabetic populations. The manufacturer chose not to pursue weight loss indication for Ozempic itself, instead creating Wegovy as the branded option for that market segment.

How Semaglutide Works in the Body for Weight Management

Semaglutide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, activating neural pathways that regulate appetite and satiety in the brain's hypothalamus. When injected, semaglutide slows gastric emptying, increases fullness signals after eating, and reduces hunger hormone levels—effects documented across multiple randomized controlled trials. These mechanisms produce weight loss independent of caloric restriction, though combining therapy with modest diet and exercise typically yields best outcomes.

The medication also improves insulin sensitivity and supports metabolic health markers like blood pressure and cholesterol. Clinical trials show patients on semaglutide lose 15–22% of body weight over 68 weeks, compared to 2–3% with placebo. Individual response varies based on genetic factors—variations in GLP1R and GIPR genes influence how effectively your body's peptide receptors engage with semaglutide, a distinction PlexusDx explores through the Precision Peptide Genetic Test.

Why Off-Label Prescribing of Ozempic for Weight Loss Became Common

Physicians have long prescribed medications off-label—using FDA-approved drugs for non-labeled conditions—when clinical evidence supports benefit and no approved alternative exists. Before Wegovy's 2021 approval, Ozempic was the only semaglutide option available, so doctors prescribed it off-label for weight loss in patients who met clinical criteria. This practice remained legal and common, especially as media coverage and celebrity endorsements amplified demand.

Off-label prescribing created supply shortages for diabetes patients who depend on Ozempic for glucose control, prompting Novo Nordisk and the FDA to issue guidance discouraging non-diabetic weight loss use of Ozempic. Additionally, insulin supply constraints and stock depletion highlighted the importance of regulated, approved channels. Compounded semaglutide from licensed 503A pharmacies emerged as a solution, offering the same active ingredient under pharmaceutical oversight while preserving supply for diabetes indications.

Compounded Semaglutide as an Accessible Alternative

Licensed 503A compounding pharmacies prepare semaglutide under FDA supervision, following the same Good Manufacturing Practices as commercial manufacturers. PlexusDx sources compounded semaglutide injection from regulated compounders, ensuring pharmaceutical quality and sterility. This approach provides patients with a clinically equivalent option without requiring Wegovy's brand-name markup or insurance coverage, starting at $149/mo.

Compounded medications are not FDA-approved in the traditional sense—they are prepared per individual prescription—but they operate within a fully regulated framework. PlexusDx serves all 50 states with no insurance requirement and HSA/FSA eligibility, removing barriers many patients face when seeking Wegovy through insurance. Your dose may need to go up as your body adapts; your price will not. Personalization through the Precision Peptide Genetic Test ($99 add-on) identifies genetic variants in GLP1R, GIPR, FTO, and MC4R pathways, helping optimize which GLP-1 compound or dosing strategy suits your unique metabolism.

Understanding Regulatory Categories: Branded vs. Compounded Semaglutide

Wegovy, Ozempic, and compounded semaglutide all contain identical or bioequivalent active ingredients but operate under different regulatory umbrellas. Branded medications undergo extensive pre-market testing, gain specific FDA approval for labeled uses, and are manufactured in FDA-inspected facilities. Compounded semaglutide skips pre-market approval but must be prepared under 503A oversight by licensed pharmacists in state-regulated facilities, with each batch meeting sterility and potency standards.

Insurance often covers branded medications for approved indications but may deny compounded alternatives despite clinical equivalence. The trade-off: compounded options reduce cost barriers and increase access for uninsured or underinsured patients seeking evidence-based weight loss therapy. PlexusDx's model prioritizes affordability and precision—fixed monthly pricing removes guesswork, and optional genetic testing maps your peptide-pathway response to select the most effective compound for your body's biology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I take Ozempic for weight loss if my doctor prescribes it?

While off-label prescribing is legal, current guidance discourages Ozempic use for weight management to preserve supply for diabetes patients. Wegovy is the approved option, or compounded semaglutide from licensed 503A pharmacies offers a regulated, affordable alternative through PlexusDx.

Is compounded semaglutide as safe and effective as branded Wegovy?

Compounded semaglutide contains the same active ingredient and is prepared under strict 503A pharmaceutical oversight. Clinical outcomes depend more on dosing precision, injection technique, and individual genetics than brand name—factors PlexusDx addresses through personalized protocols and optional genetic testing.

How much does PlexusDx semaglutide cost compared to Wegovy?

PlexusDx compounded semaglutide injection starts at $149/mo flat—no flat per-compound pricing increases. Wegovy typically costs $900–$1,350/mo without insurance. PlexusDx accepts HSA/FSA funds and requires no membership or insurance, making it accessible to all 50 states.

What side effects should I expect with semaglutide?

Common effects include nausea, vomiting, diarrhea, and constipation, typically mild and temporary as your body adjusts. Serious risks (pancreatitis, thyroid tumors in animal studies) are rare but require medical monitoring. PlexusDx pairs therapy with telehealth oversight to track tolerance and optimize your dose safely.

How can the Precision Peptide Genetic Test help my semaglutide response?

The test identifies your genetic variants in GLP1R, GIPR, FTO, and MC4R genes—key players in appetite regulation and weight loss response. PlexusDx maps 14 pathways and 150+ insights to predict which GLP-1 compound (semaglutide, tirzepatide, or dual formulas) may work best for your metabolism, available as a $99 add-on after your first month of treatment.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves